Espicom's generics company reports will help you to understand the dynamic and complex issues affecting the business of leading generic industry players. These informative reports provide an insight into the company, covering the structure of the business, the most recent quarterly and annual financial results, information on the company's active product lines and ANDA approvals, along with a review of major developments, such as M&A activity, strategic alliances, and litigation. Founded in 1942, Lannett operates from a facility situated on 4.5 acres in north-east Philadelphia, Pennsylvania, and began trading on the American Stock Exchange in 2002. The company manufactures and distributes generics, and historically has sold them under trade or brand names.

Lannett tries to avoid joining the scrum developing off-patent blockbuster drugs, but looks instead to developing other generic drugs with more secure markets and less competition. Additionally, the company pursues long-term alliances with API suppliers. Lannett also licenses the marketing of its products to other manufacturers. The company currently has 13 ANDAs pending with the FDA, and another 56 products in its pipeline.

The company experienced a major decline in sales in 2005, due largely to price reductions, and made a large net loss as a result. In fiscal 2006, the company has reported a return to profitability, and a rise in sales of 42.7%. Lannett attributes this improvement to new product launches and strategic alliances.

Lannett acquired a new leased facility in August 2006 in Philadelphia, to serve as its main warehouse and future HQ.